Last updated on October 2018

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

Brief description of study

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.

Clinical Study Identifier: NCT03547583

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Multiprofile Hospital for Active Treatment Pazardzhik
Pazardzhik, Bulgaria
  Connect »